DIO Corporation (KOSDAQ:039840)
14,100
-70 (-0.49%)
Jun 2, 2026, 3:30 PM KST
DIO Corporation Revenue
DIO Corporation had revenue of 41.32B KRW in the quarter ending March 31, 2026, with 15.41% growth. This brings the company's revenue in the last twelve months to 169.60B, up 40.75% year-over-year. In the year 2025, DIO Corporation had annual revenue of 164.08B with 37.13% growth.
Revenue (ttm)
169.60B
Revenue Growth
+40.75%
P/S Ratio
1.12
Revenue / Employee
367.09M
Employees
479
Market Cap
189.16B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 164.08B | 44.43B | 37.13% |
| Dec 31, 2024 | 119.65B | -36.17B | -23.21% |
| Dec 31, 2023 | 155.82B | 24.51B | 18.67% |
| Dec 31, 2022 | 131.31B | -18.73B | -12.48% |
| Dec 31, 2021 | 150.04B | 29.98B | 24.97% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4.81T |
| Celltrion | 4.47T |
| Samsung Epis Holdings | 1.51T |
| Chong Kun Dang Holdings | 952.66B |
| Daewon Pharmaceutical | 605.66B |
| Whan In Pharm | 266.19B |
| ALTEOGEN | 203.76B |
| REYON Pharmaceutical | 145.22B |